Pfizer shares jump over 2% after launch of next-gen 20-valent pneumococcal vaccine in India
Shares of Pfizer Limited rose 2.07% to Rs 5,165.50 on Tuesday, August 12, following the company's announcement of the launch of its next-generation 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV20) for adults in India. The stock traded in a range of Rs 5,098.50 to Rs 5,200.00 during the session, with a market capitalization of Rs 2.36 lakh crore and a price-to-earnings ratio of 30.79.
Launched on August 11, 2025, PCV20 is designed to protect against 20 clinically relevant serotypes of Streptococcus pneumoniae, offering the broadest coverage among conjugate vaccines available in India. Approved for adults aged 18 years and older, it is administered as a single-dose shot, potentially eliminating the need for a second dose.
Pfizer stated that the vaccine will help address the growing need for adult immunization, especially among those over 50 years of age and individuals with chronic conditions such as asthma, COPD, chronic kidney disease, and diabetes. The company noted that the introduction of PCV20 builds on its 25-year legacy in pneumococcal vaccine innovation and strengthens its commitment to preventive healthcare in India.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving Precigen and Pfizer, as well as updates from the Institute for Clinical and Economic Review, Superluminal Medicines and Generation Bio that you may have missed. The Food and Drug Administration granted full approval to a first-of-its-kind treatment for recurrent respiratory papillomatosis, a rare and potentially life-threatening condition caused by persistent HPV infections. Thursday's clearance of Precigen's Papzimeos, an immunotherapy that helps clear HPV-infected cells, was based on study results showing a little more than half of drug recipients didn't need surgery within a year of therapy. Center for Biologics Evaluation and Research director Vinay Prasad, who rejoined the FDA this week, described the approval as proof 'randomized trials are not always needed to approve medical products.' That statement should be 'reassuring' to biotech investors concerned about stricter regulatory standards under Prasad, wrote Cantor Fitzgerald analyst Jennifer Kim. Precigen shares rose higher Friday on the news. — Ben Fidler An experimental Pfizer drug for sickle cell disease failed to meet its goal in a Phase 3 study, the company said Friday. Testing showed that treatment with inclacumab, a drug Pfizer acquired via its 2022 buyout of Global Blood Therapeutics, failed to significantly reduce versus placebo the pain crises people with sickle cell often experience. Pfizer said it would share analyses of the data with the scientific and patient community in 'due course.' Last year, the company pulled from market another sickle cell drug, Oxbryta, that it gained from Global Blood, citing safety concerns. The company plans to provide updates on Oxbryta and a third Global Blood drug, the experimental osivelotor, when they become available. — Ned Pagliarulo Eli Lilly will collaborate with biotechnology startup Superluminal Medicines to develop new drugs for cardiometabolic diseases and obesity. Through the alliance, the two intend to discover and advance small molecule medicines aimed at undisclosed G protein-coupled receptor, or GPCR, targets 'relevant' to those conditions. Lilly will receive exclusive rights to the compounds emerging from the deal, while Superluminal could get up to $1.3 billion in total payouts, including an unspecified upfront payment as well as an equity investment, the companies said Thursday. — Ben Fidler Autolus Therapeutics is delaying launching its leukemia cell therapy Aucatzyl in Europe following approval there as the company 'evaluates potential pricing and feasibility of market entry opportunities' in some countries. Launch in Germany is on hold and Autolus 'does not anticipate any EU sales of Aucatzyl in 2025 and 2026,' the company said in its second quarter earnings report. In the U.K., where Aucatzyl has also been approved, a government cost-effectiveness monitor has initially decided not to pay for it. Autolus said it 'will continue to work towards a pathway for patient access to therapy in the U.K.' Approved by the Food and Drug Administration in November 2024, Aucatzyl earned just shy of $30 million in sales in the first six months of 2025, all from the U.S. — Jonathan Gardner Generation Bio revealed preclinical results suggesting a delivery technology it's developing can effectively send nucleic acid payloads into T cells. But the company also said this week that it may not be able to raise the funds to prove that approach works in humans and, as a result, began a strategic review that could end in a sale or merger. Generation will lay off roughly 90% of its workforce, including all of its research and development staff, by the end of October. Company shares climbed 60%, though they've lost much of their value since the company's initial public offering in 2020. — Ben Fidler Recommended Reading Eli Lilly's Julie Gilmore on finding up-and-coming companies and backing small biotechs Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Epoch Times
a day ago
- Epoch Times
Pfizer COVID-19 Vaccine May Become Unavailable for Some Children
The Pfizer-BioNTech COVID-19 vaccine may become unavailable for some children, according to an email sent to state health officials. The Food and Drug Administration, which has granted Emergency Use Authorization (EUA) for the vaccine for some children, 'recently notified Pfizer of its intent to potentially NOT renew the EUA,' the Centers for Disease Control and Prevention said in an Aug. 8 memo, a copy of which was reviewed by The Epoch Times.
Business Upturn
3 days ago
- Business Upturn
Did you know? Olympic hockey hero Dr Vece Paes also shaped Indian cricket with BCCI role
By Aditya Bhagchandani Published on August 14, 2025, 10:10 IST Not many know that Dr Vece Paes — 1972 Olympic hockey bronze medallist and father of tennis icon Leander Paes — had a long-standing connection with Indian cricket too. A stalwart in sports medicine, Dr Paes served as a medical consultant for the Board of Control for Cricket in India (BCCI) and the Asian Cricket Council for decades, overseeing anti-doping education and player welfare. His expertise was sought at ATP tennis tournaments, Davis Cup ties, and even the Indian Super League (ISL). In 2021, a special cricket tournament — the Dr Vece Paes Cricket Cup — was launched in his honour at the historic Calcutta Cricket and Football Club (CC&FC). Leander Paes himself turned up in pads for the Doctors' XI, teaming up with former India all-rounder Irfan Pathan to celebrate his father's legacy. The event is now an annual Republic Day tradition in Kolkata. From Olympic glory to shaping sports medicine in India, Dr Vece Paes leaves behind a legacy that spans far beyond the hockey field. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
